Sunday, November 27, 2022
HomeExclusiveWhat Is The Survival Rate For Her2 Negative Breast Cancer

What Is The Survival Rate For Her2 Negative Breast Cancer

The Following Statistics Are A Little Old Now They Are Much Better

Health Tips – HER2-Positive Breast Cancer

There are of course many factors that contribute to the survival of breast cancer. However, some older studies show that only about 60%of patients with HER-2 positive status invasive breast cancer are disease free after 10 years.

In addition, about 65% survive overall .

And, a greater number of HER-2 positive patients succumb to the illness during the first five years than those who are negative for HER-2 overexpression.

At the same time, all other factors assumed to be equal, patients with negative HER-2 status tumors tend to be disease free at a rate of 75% over 10 years and have a slightly higher overall survival rate.

From this, we can informally estimate that women with breast cancer which overexpresses HER-2 are about 10% more likely to have significant difficulties and ultimately succumb to the disease within the first five years, than those who do not.

Because some of the Incidence and Prognosis rates are a little old now check out our brand new Index of Posts on Survival Rates.

Her2+ Status Cancer Stage And Survival

The importance of HER2 status for survival will depend on how far the cancer has spread. If itâs only in the breast, then it wonât make much difference. Most women in the early stage of the disease do well because a surgeon can remove the tumor.

Itâs when a breast tumor grows and spreads to lymph nodes or farther away in the body that HER2 status becomes more important for treatment and survival. Thatâs because there are now drugs that target HER2, but these work only for cancers that are HER2+. A common drug for HER2+ breast cancer is trastuzumab , but there are others. Because there are more treatments, women with more advanced HER2+ breast cancers today will on average have better survival rates than those with more advanced HER2- breast cancers.

Show Sources

Is Her2 Breast Cancer Curable

The chances of successfully treating HER2 breast cancer is high if the cancer is detected in early stages. HER2 cancers, however, are often high grade tumors in stage III at the time of diagnosis. If HER2 cancer has metastasized at the time of diagnosis, it is treatable but not curable in most individuals.

With the development of medications that specifically target HER2 proteins, HER2-positive breast cancers now have a much better outlook than in the past. HER2-positive cancers that have been in remission for five years are less likely to recur.

Also Check: Whats The Youngest You Can Get Breast Cancer

Hormone Receptor Status And Prognosis

Hormone receptor status is related to the risk of breast cancer recurrence.

Hormone receptor-positive tumors have a slightly lower risk of breast cancer recurrence than hormone receptor-negative tumors in the first 5 years after diagnosis .

After 5 years, this difference begins to decrease and over time, goes away .

Recommended Reading: Can Stage 1 Breast Cancer Be Cured

Factors That Can Influence Survival Rate

HER2

There are a number of lifestyle factors that can influence outcomes for women with HER2 positive breast cancer. To give themselves the best chance at achieving a favorable outcome, it is recommended that patients:

  • Maintain a healthy weight
  • Eat a healthy and balanced diet
  • Remain physically active, if possible
  • Avoid tobacco use

Moffitt Cancer Center is a leader in cancer research and treatment. We provide our patients with individualized treatment plans and a full range of supportive care services to ensure all their needs are met as they undergo treatment. As a result, we are able to achieve the best possible outcomes and quality of life for our patients.

Those who have questions about the survival rate for HER2 positive breast cancer are encouraged to consult with a physician at Moffitt. To request an appointment with or without a referral, call or submit a new patient registration form online.

  • BROWSE

Recommended Reading: Stage 3 B Cancer

Hormone Receptor Status Can Influence Survival Rates

When a breast cancer tumor is sent for histological analysis, one of the characteristics of the report will be the hormone receptor status of the tumor.

Estrogen receptor and progesterone receptor positive tumors tend to respond better to chemotherapy. Chemotherapy tends to be the treatment of choice for stage III and IV breast cancers.

Breast cancers which are triple negative tend to have the least favourable survival rates, regardless of breast cancer stage.

One 2011 research study looked at 269 triple-negative breast cancer patients all treated at the same institution between 2000 and 2006.

This study found that the average age at diagnosis was 55.3 years. The 5 year disease-free survival rate for the whole group was 68.2%. However, the 5 year overall survival rate for the entire group was higher at 74.5%.

Risk of recurrence was higher in the first 3 years following the initial diagnosis. However, the recurrence rate declined significantly after this initial 3 year period.

Other factors that were found to be important factors on survival rates were:-

  • Lymph node status
  • Lymphovascular invasion
  • Age: Ladies older than 65 years had a poorer prognosis

However, ER and PR status tends to have more of an influence on survival than HER2 status. Patients with ER+/PR+/HER2- subtype of breast cancer have an estimated 5-year survival rate of 87.8%.

Immunohistochemical Evaluation Of Er Pgr And Her2 Status

Tumors were tested for estrogen receptor and progesterone receptor by enzyme immunoassay before 2001, by either EIA or immunohistochemistry in 200203, and by IHC from 2004 onwards. ER and PgR positivity was defined as a value greater than 10 fmol/mg protein before the autumn of 2009, and a value greater than 1 fmol/mg protein from then on. The subtype of HR positivity was defined as ER-positive and/or PgR-positive. HER2-positive status was defined as IHC staining for HER2 protein of 3+ intensity, or 2+ with the presence of amplification of the HER2 gene by fluorescence in situ hybridization . HER2-negative status was defined as IHC staining for HER2 protein of 01+ intensity, or 2+ with absence of amplification of the HER2 gene by FISH. The data of HER2 status before 2002 were not available for patients. It is because HER2 testing was approved in Japan in 2002, and this test was not performed routinely in clinical practice. We evaluated samples based on the guidelines for HER2 testing produced by the Pathological Committee for Optimal use of trastuzumab since 2001 , and the American Society of Clinical Oncology/College of American Pathologists guideline . Patients with a prior-history of trastuzumab therapy without histologically-proven HER2-positive status, were also defined as a clinically HER2-enriched subtype.

Also Check: How Long Can You Live Stage 4 Breast Cancer

What Are The Stages Of Breast Cancer

Breast cancer is staged by the size of the tumor and extent of spread. Breast cancers are also graded from one to three, based on how abnormal the cancer cells look and how fast they grow. One is low grade cancer and three is high grade cancer that grows and spreads rapidly.

The four stages of breast cancer are:

  • Stage I: The tumor is relatively small and localized to the original site, with possible spread to the sentinel lymph nodes, which are the first lymph nodes the cancer is likely to spread to.
  • Stage II: The tumor has grown and spread to a few nearby lymph nodes.
  • Stage III: The tumor has grown into many lymph nodes and other tissue in the breast.
  • Stage IV: The cancer has spread to distant parts of the body.

Another highly detailed classification system is the TNM classification system based on tumor size, lymph node involvement and metastatic spread.

Regional Relapse Following Breast Cancer Treatment Carries A Poorer Prognosis

An Overview of the MERIBEL Study in HER2-Negative Breast Cancer

Most localized breast cancers are treated by either breast conserving surgery with radiation therapy, or by mastectomy.

A medical study from 2010 estimates that around 40% of all women with breast cancer will suffer a recurrence.

The prognosis following a breast cancer recurrence is influenced by a number of factors. These include:-

  • The Disease Free Interval: This is the time elapsed from diagnois and treatment of the first breast cancer to the recurrence
  • The location of the recurrence: Whether the recurrence is in the same breast , or if it recurs in the contralateral breast, regional lymph nodes, or the chest wall .

Patients with breast cancer relapses are typically generally treated with either a salvage mastectomy, or radiation to the chest wall, regional lymph nodes, or both.

Systemic therapy may be implemented at this point. However, this will be determined on an individual basis, based on the likelihood of distant metastasis, characteristics of the tumor, and other factors.

Don’t Miss: Baking Soda And Honey Cancer Cure

What Are The Survival Rates For Breast Cancer

Patients with node-negative disease have an overall 10-year survival rate of 70% and a 5-year recurrence rate of 19%. In patients with lymph nodes that are positive for cancer, the recurrence rates at 5 years are as follows:

  • One to three positive nodes 30-40%
  • Four to nine positive nodes 44-70%
  • 10 positive nodes 72-82%

Hormone receptorpositive tumors generally have a more indolent course and are responsive to hormone therapy. ER and PR assays are routinely performed on tumor material by pathologists immunohistochemistry is a semiquantitative technique that is observer- and antibody-dependent.

This prognostic information can guide physicians in making therapeutic decisions. Pathologic review of the tumor tissue for histologic grade, along with the determination of ER/PR status and HER2 status, is necessary for determining prognosis and treatment. Evaluation of lymph node involvement by means of sentinel lymph node biopsy or axillary lymph node dissection is generally necessary as well.

References
  • Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar. 17 :367-77. . .

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan. 71 :7-33. . .

  • Tukysa . Bothell, WA: Seattle Genetics, Inc. April 2020. Available at .

  • Regional Recurrence Within Three Years Carries A Less Favorable Prognosis But Overall Survival Statistics Are Still Good

    Generally speaking, if the breast cancer returns regionally lymph nodes) within the first five years following original treatment, the overall likelihood of survival is thought to be somewhat poorer.

    Five-year overall survival after an isolated chest wall recurrence is 68% and after intra-breast recurrence it is 81%.

    In one 2010 medical research study, the ten year overall survival rate was estimated at 84% for women without recurrence. However, this figure goes down to 49% for women with a locoregional recurrence and 72% for women with a second primary tumour.

    A large 2015 study examined the impact of the time of the disease free interval on survival rates. For women with a locoregional recurrence that happened in the first 18 months, the ten year overall survival rate is around 30%. The overall 10 year survival rate for those whose recurrence happened within 3 years goes up to 50%. Furthermore, for those who suffered a recurrence after 3 years the ten year overall survival rate increases to 70%.

    This recent study clearly demonstrates that the longer the time span since the primary prognosis and treatment to the recurrence, the better the long-term prognosis.

    33 30

    The rate of distance breast cancer metastasis and overall survival is most favorable for women in which the recurrence occurred locally and after five years.

    However, women with a same-breast recurrence within five years have a distant metastasis rate of about 61%, which are slightly poorer odds.

    You May Like: Nipple Piercing And Breast Cancer

    Trastuzumab Provides A Comparable Prognosis In Patients With Her2

    • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background and Purpose: We investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC.

    Materials and Methods: This was post hoc analyses of data of 793 BC patients from a randomized controlled trial comparing post-mastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy. Survival rates were analyzed by the KaplanMeier method and compared by the log-rank test.

    Results: Patients were classified into three groups: HER2-negative , HER2-positve with trastuzumab , and HER2-positive without trastuzumab . The HER2+ + T group had significantly lower locoregional recurrence , distant metastasis and higher disease-free survival at 5 years than that of the HER2+ T group . The HER2 group had significantly lower LRR , DM and higher DFS at 5 years than that of the HER2+ T group . The difference in LRR, DM and DFS at 5 years was not significant between the HER2+ + T group and HER2 group . Different annual LRR patterns was found among groups according to HR status.

    Survival Rates For Her2

    HER2

    Cancer survival statistics are typically reported using a 5-year survival rate. This is the percentage of individuals that are still living 5 years after their diagnosis.

    Survival rates can vary based off of the subtype of breast cancer that you have. A publication from the reports 5-year survival rates for HER2-negative breast cancers as:

    • 92 percent for HER2-negative, HR-positive breast cancer
    • 77 percent for triple-negative breast cancer

    Keep in mind that HER2 and HR status arent the only factors that can influence outlook. Other important factors at diagnosis include:

    • the stage of the cancer
    • the specific type of breast cancer
    • your age and overall health

    Read Also: How Long Does Breast Cancer Take To Develop

    Age And Stage For Breast Cancer Survival

    Research over the years has generally shown that women under 40 years have a poorer than average prognosis. Interestingly, this factor is particularly relevant when the breast cancer is axillary node negative.

    A medical study published in 2015 examined 4,453 Swedish women diagnosed with invasive breast cancer between 1961 and 1991 regarding age at diagnosis.

    This research showed that women under 40 years had a higher mortality rate both for 5 year and 10 year survival rate.

    However, older ladies between ages 70 and 79 and over 80 years had a higher mortality rate in both the 5 and 10 year follow up periods. The statistically worst outcome, after all adjustments for other factors, is for ladies over 80 years.

    Furthermore, an earlier taken from SEER statistics between the years of 1988 to 2003 found that women under 40 years had lower rates of survival for stage I and II breast cancers.

    Conversely, younger women tended to have a more favourable chance of survival at stage III and IV compared with those over 70 years of age.

    Prognosis And Survival For Breast Cancer

    If you have breast cancer, you may have questions about your prognosis. A prognosis is the doctors best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type, stage and characteristics of your cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis.

    A prognostic factor is an aspect of the cancer or a characteristic of the person that the doctor will consider when making a prognosis. A predictive factor influences how a cancer will respond to a certain treatment. Prognostic and predictive factors are often discussed together. They both play a part in deciding on a treatment plan and a prognosis.

    Doctors use different prognostic and predictive factors for newly diagnosed and recurrent breast cancers.

    Read Also: Is Weight Loss A Symptom Of Breast Cancer

    Why Receptor Status Matters

    Breast cancer is not a single disease, and researchers now have the ability to break down breast cancer into different subtypes based on the receptor status of the tumors. Among the variations between different types of breast cancers are the proteins found on cell surfaces, which are involved tumor growth. These proteins are related to the genetic material of cancer cells.

    For example, with estrogen receptor-positive breast cancer, estrogen binds to specific receptors on breast cancer cells, stimulating proliferation. Similarly, HER2 receptors on the surface of breast cancer cells are stimulated by HER2 protein, promoting the growth and spread of breast cancer.

    It’s important to note, however, that all breast cellsboth cancerous and noncanceroushave HER2 receptors on their surfaces. The difference is that HER2-positive breast cancer cells have 40 to 100 times more receptors than HER2-negative breast cancer cells or normal breast cells. In positive cases, the abundance of receptors fuels the cancer.

    Breast Cancer Discussion Guide

    Get our printable guide for your next healthcare provider’s appointment to help you ask the right questions.

    Where Do These Numbers Come From

    Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer

    The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results database, maintained by the National Cancer Institute , to provide survival statistics for different types of cancer.

    The SEER database tracks 5-year relative survival rates for breast cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages . Instead, it groups cancers into localized, regional, and distant stages:

    • Localized: There is no sign that the cancer has spread outside of the breast.
    • Regional: The cancer has spread outside the breast to nearby structures or lymph nodes.
    • Distant: The cancer has spread to distant parts of the body such as the lungs, liver or bones.

    Read Also: Does Getting Punched In The Breast Cause Cancer

    What Are Symptoms Of Triple Negative Breast Cancer

    TNBC symptoms are the same as other common breast cancers. And many breast cancer symptoms are similar to other less serious conditions. That means having certain symptom doesnt mean you have breast cancer. Possible breast cancer symptoms include:

    • A new lump or mass.
    • Swelling in all or part of a breast.
    • Dimpled skin.
    • Nipple retraction, when your nipple turns inward.
    • Nipple or breast skin thats dry, flaking, thickened or red.
    • Nipple discharge that is not breast milk.
    • Swollen lymph nodes. This symptom happens when breast cancer spreads to the lymph nodes under your arm or near your collarbone.

    RELATED ARTICLES

    Popular Articles